Skip to main content
SpringerLink
Log in

Hydergine ®

Pharmacologic and Clinical Facts

  • Book
  • © 1988

Overview

Authors:
  1. Claude Weil

    1. Pharmaceutical Division, SANDOZ Ltd., Basle, Switzerland

    View author publications

    You can also search for this author in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages I-VIII
    Download chapter PDF

  2. Introduction and Background Information

    • Claude Weil
    Pages 1-4

  3. Basic Pharmacologic Properties: Peripheral Effects on Neurotransmission

    • Claude Weil
    Pages 5-11

  4. Basic Pharmacologic Properties: Central Effects

    • Claude Weil
    Pages 13-52

  5. Effects of Co-Dergocrine on the Cardiovascular System

    • Claude Weil
    Pages 53-60

  6. Effects of Co-Dergocrine on Other Organs and Cells

    • Claude Weil
    Pages 61-64

  7. The Clinical Pharmacology of Co-Dergocrine in Age-Related Cerebral Insufficiency

    • Claude Weil
    Pages 65-86

  8. Co-Dergocrine in Various Cardiovascular and Cerebral Indications

    • Claude Weil
    Pages 87-90

  9. Biopharmaceutical Aspects

    • Claude Weil
    Pages 91-93

  10. Toxicologic Considerations

    • Claude Weil
    Pages 95-97

  11. Back Matter

    Pages 99-111
    Download chapter PDF
Back to top

Keywords

About this book

Ten years have elapsed since the publication in 1978 of Vol. 49 of the Handbook of Experimental Pharmacology [41], a toOO-page survey of the data then available on Ergot Alkaloids and Related Compounds. A booklet published in 1979 presented the in­ formation on one of these compounds, namely co-dergocrine (Hydergine@), as extracted from the Handbook and updated to take the latest developments into account [42]. Co-dergocrine had at the time been on the market for 30 years and had given rise to over 2000 papers, so that one might have felt justified in thinking that its scientific history had virtually come to an end. It has now become obvious that such a view would have been wide of the mark. Research on the pharmacology and clinical pharmacology of co-dergocrine has remained as active as ever. The resulting obsolescence of the 1979 booklet made necessary the preparation of the present version. Like its predecessor, it is intended as an inventory of findings and facts rather than a work dealing with their interpretation.

Authors and Affiliations

  • Pharmaceutical Division, SANDOZ Ltd., Basle, Switzerland

    Claude Weil

Bibliographic Information

  • Book Title: Hydergine ®

  • Book Subtitle: Pharmacologic and Clinical Facts

  • Authors: Claude Weil

  • DOI: https://doi.org/10.1007/978-3-642-73702-2

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1988

  • Softcover ISBN: 978-3-642-73704-6Published: 23 December 2011

  • eBook ISBN: 978-3-642-73702-2Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: VIII, 111

  • Topics: Pharmacology/Toxicology, Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation